NASDAQ:KALA - Kala Pharmaceuticals Stock Price, Price Target & More

$15.96 +0.19 (+1.20 %)
(As of 04/24/2018 12:30 PM ET)
Previous Close$15.77
Today's Range$15.83 - $16.08
52-Week Range$11.81 - $26.75
Volume12,938 shs
Average Volume319,618 shs
Market Capitalization$392.90 million
P/E Ratio-2.73
Dividend YieldN/A
BetaN/A

About Kala Pharmaceuticals (NASDAQ:KALA)

Kala Pharmaceuticals logoKala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles technology. The company's product candidates include KPI-121 1.0%, which has completed Phase 3 clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-121 0.25% that is in Phase 3 clinical trials for the temporary relief of the signs and symptoms of dry eye disease. It also develops KPI-285, a receptor kinase inhibitor, which is in preclinical studies for the treatment of various retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Waltham, Massachusetts.

Receive KALA News and Ratings via Email

Sign-up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KALA
CUSIPN/A
Phone781-996-5252

Debt

Debt-to-Equity Ratio0.13%
Current Ratio7.97%
Quick Ratio7.97%

Price-To-Earnings

Trailing P/E Ratio-2.73
Forward P/E Ratio-8.06
P/E GrowthN/A

Sales & Book Value

Annual Sales$40,000.00
Price / Sales9,799.44
Cash FlowN/A
Price / CashN/A
Book Value$3.66 per share
Price / Book4.36

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees37
Outstanding Shares24,560,000

How to Become a New Pot Stock Millionaire

Kala Pharmaceuticals (NASDAQ:KALA) Frequently Asked Questions

What is Kala Pharmaceuticals' stock symbol?

Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."

How were Kala Pharmaceuticals' earnings last quarter?

Kala Pharmaceuticals (NASDAQ:KALA) issued its quarterly earnings data on Monday, March, 26th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by $0.09. View Kala Pharmaceuticals' Earnings History.

What price target have analysts set for KALA?

5 brokers have issued 1-year price targets for Kala Pharmaceuticals' shares. Their forecasts range from $19.00 to $46.00. On average, they expect Kala Pharmaceuticals' stock price to reach $35.80 in the next twelve months. View Analyst Ratings for Kala Pharmaceuticals.

Are investors shorting Kala Pharmaceuticals?

Kala Pharmaceuticals saw a decline in short interest in March. As of March 15th, there was short interest totalling 1,165,475 shares, a decline of 21.7% from the February 28th total of 1,488,996 shares. Based on an average daily trading volume, of 277,453 shares, the days-to-cover ratio is presently 4.2 days. Approximately 8.0% of the shares of the stock are sold short.

Who are some of Kala Pharmaceuticals' key competitors?

Who are Kala Pharmaceuticals' key executives?

Kala Pharmaceuticals' management team includes the folowing people:
  • Mr. Mark T. Iwicki, Exec. Chairman and Chief Exec. Officer (Age 52)
  • Dr. Hongming Chen Sc.D., Chief Scientific Officer (Age 47)
  • Dr. Kim Brazzell Ph.D., Chief Medical Officer (Age 65)
  • Dr. Justin Hanes Ph.D., Founder & Chair of the Scientific Advisory Board
  • Ms. Mary Reumuth CPA, CFO & Treasurer (Age 43)

When did Kala Pharmaceuticals IPO?

(KALA) raised $90 million in an IPO on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

Has Kala Pharmaceuticals been receiving favorable news coverage?

Press coverage about KALA stock has trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Kala Pharmaceuticals earned a coverage optimism score of 0.09 on Accern's scale. They also gave press coverage about the company an impact score of 47.17 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of Kala Pharmaceuticals?

Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kala Pharmaceuticals' stock price today?

One share of KALA stock can currently be purchased for approximately $15.96.

How big of a company is Kala Pharmaceuticals?

Kala Pharmaceuticals has a market capitalization of $392.90 million and generates $40,000.00 in revenue each year. The company earns $-42,210,000.00 in net income (profit) each year or ($5.84) on an earnings per share basis. Kala Pharmaceuticals employs 37 workers across the globe.

How can I contact Kala Pharmaceuticals?

Kala Pharmaceuticals' mailing address is 100 BEAVER STREET SUITE 201, WALTHAM MA, 02453. The company can be reached via phone at 781-996-5252 or via email at [email protected]


MarketBeat Community Rating for Kala Pharmaceuticals (KALA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  84 (Vote Outperform)
Underperform Votes:  94 (Vote Underperform)
Total Votes:  178
MarketBeat's community ratings are surveys of what our community members think about Kala Pharmaceuticals and other stocks. Vote "Outperform" if you believe KALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KALA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Kala Pharmaceuticals (NASDAQ:KALA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Kala Pharmaceuticals in the last 12 months. Their average twelve-month price target is $35.80, suggesting that the stock has a possible upside of 124.31%. The high price target for KALA is $46.00 and the low price target for KALA is $19.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $35.80$35.80$36.80$36.80
Price Target Upside: 124.31% upside139.95% upside112.35% upside112.84% upside

Kala Pharmaceuticals (NASDAQ:KALA) Consensus Price Target History

Price Target History for Kala Pharmaceuticals (NASDAQ:KALA)

Kala Pharmaceuticals (NASDAQ:KALA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/25/2018Wells FargoReiterated RatingOutperform -> Outperform$24.00 -> $19.00MediumView Rating Details
12/22/2017WedbushReiterated RatingOutperform$46.00MediumView Rating Details
11/19/2017JPMorgan ChaseSet Price TargetBuy$35.00N/AView Rating Details
8/15/2017OppenheimerInitiated CoverageOutperform -> Outperform$46.00 -> $46.00LowView Rating Details
8/14/2017Bank of AmericaInitiated CoverageBuy -> Buy$33.00HighView Rating Details
(Data available from 4/24/2016 forward)

Earnings

Kala Pharmaceuticals (NASDAQ:KALA) Earnings History and Estimates Chart

Earnings by Quarter for Kala Pharmaceuticals (NASDAQ:KALA)

Kala Pharmaceuticals (NASDAQ:KALA) Earnings Estimates

2018 EPS Consensus Estimate: ($2.10)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.49)($0.49)($0.49)
Q2 20181($0.52)($0.52)($0.52)
Q3 20181($0.53)($0.53)($0.53)
Q4 20181($0.56)($0.56)($0.56)

Kala Pharmaceuticals (NASDAQ KALA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/26/2018Q4 2017($0.37)($0.46)ViewListenView Earnings Details
11/7/2017Q3 2017($0.4250)($0.56)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Kala Pharmaceuticals (NASDAQ:KALA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Kala Pharmaceuticals (NASDAQ KALA) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 72.30%
Insider Trading History for Kala Pharmaceuticals (NASDAQ:KALA)
Institutional Ownership by Quarter for Kala Pharmaceuticals (NASDAQ:KALA)

Kala Pharmaceuticals (NASDAQ KALA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/8/2018Orbimed Advisors LlcMajor ShareholderBuy25,000$12.93$323,250.00View SEC Filing  
2/1/2018Orbimed Advisors LlcMajor ShareholderBuy362,240$15.00$5,433,600.00View SEC Filing  
1/29/2018Orbimed Advisors LlcMajor ShareholderBuy72,760$14.97$1,089,217.20View SEC Filing  
1/26/2018Orbimed Advisors LlcMajor ShareholderBuy22,760$14.93$339,806.80View SEC Filing  
1/24/2018Orbimed Advisors LlcMajor ShareholderBuy64,637$14.91$963,737.67View SEC Filing  
1/22/2018Orbimed Advisors LlcMajor ShareholderBuy75,000$14.98$1,123,500.00View SEC Filing  
1/19/2018Orbimed Advisors LlcMajor ShareholderBuy74,931$14.95$1,120,218.45View SEC Filing  
1/12/2018Orbimed Advisors LlcMajor ShareholderBuy240,484$13.28$3,193,627.52View SEC Filing  
1/10/2018Orbimed Advisors LlcMajor ShareholderBuy170,338$12.83$2,185,436.54View SEC Filing  
7/25/2017Longitude Capital Partners Ii,Major ShareholderBuy215,000$15.00$3,225,000.00View SEC Filing  
7/25/2017Orbimed Advisors LlcInsiderBuy319,333$15.00$4,789,995.00View SEC Filing  
7/25/2017Rajeev M ShahDirectorBuy533,333$15.00$7,999,995.00View SEC Filing  
7/20/2017Associates L.L.C. CdkMajor ShareholderBuy215,000$15.00$3,225,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Kala Pharmaceuticals (NASDAQ KALA) News Headlines

Source:
DateHeadline
-$0.45 Earnings Per Share Expected for Kala Pharmaceuticals (KALA) This Quarter-$0.45 Earnings Per Share Expected for Kala Pharmaceuticals (KALA) This Quarter
www.americanbankingnews.com - April 20 at 9:18 PM
Brokers Set Expectations for Kala Pharmaceuticals Q1 2018 Earnings (KALA)Brokers Set Expectations for Kala Pharmaceuticals' Q1 2018 Earnings (KALA)
www.americanbankingnews.com - April 20 at 7:10 AM
Kala Pharmaceuticals (KALA) Earns Buy Rating from Analysts at Bank of AmericaKala Pharmaceuticals (KALA) Earns Buy Rating from Analysts at Bank of America
www.americanbankingnews.com - April 10 at 5:03 PM
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - April 10 at 10:55 AM
Kala Pharmaceuticals (KALA) Given Average Recommendation of "Buy" by BrokeragesKala Pharmaceuticals (KALA) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 10 at 2:01 AM
Kala Pharmaceuticals to Present at the 2018 American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) and at the Ophthalmology Innovation Summit at ASCRSKala Pharmaceuticals to Present at the 2018 American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) and at the Ophthalmology Innovation Summit at ASCRS
finance.yahoo.com - April 9 at 10:53 AM
Kala Pharmaceuticals (KALA) Downgraded to Sell at Zacks Investment ResearchKala Pharmaceuticals (KALA) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - April 7 at 11:22 AM
Kala Pharmaceuticals (KALA) Lifted to Buy at BidaskClubKala Pharmaceuticals (KALA) Lifted to Buy at BidaskClub
www.americanbankingnews.com - April 5 at 12:30 AM
Zacks Investment Research Upgrades Kala Pharmaceuticals (KALA) to HoldZacks Investment Research Upgrades Kala Pharmaceuticals (KALA) to Hold
www.americanbankingnews.com - April 4 at 6:26 AM
Kala Pharmaceuticals Inc (KALA) Expected to Post Earnings of -$0.44 Per ShareKala Pharmaceuticals Inc (KALA) Expected to Post Earnings of -$0.44 Per Share
www.americanbankingnews.com - April 3 at 11:18 PM
Kala Pharmaceuticals Appoints Eric Trachtenberg as General Counsel and Corporate SecretaryKala Pharmaceuticals Appoints Eric Trachtenberg as General Counsel and Corporate Secretary
finance.yahoo.com - April 3 at 10:55 AM
Short Interest in Kala Pharmaceuticals Inc (KALA) Drops By 21.7%Short Interest in Kala Pharmaceuticals Inc (KALA) Drops By 21.7%
www.americanbankingnews.com - March 31 at 2:56 AM
Kala Pharmaceuticals 2017 Q4 - Results - Earnings Call SlidesKala Pharmaceuticals 2017 Q4 - Results - Earnings Call Slides
seekingalpha.com - March 28 at 10:37 AM
Kala Pharmaceuticals, Inc. (KALA) Q4 2017 Earnings Conference Call TranscriptKala Pharmaceuticals, Inc. (KALA) Q4 2017 Earnings Conference Call Transcript
finance.yahoo.com - March 27 at 10:55 AM
Kala Pharmaceuticals (KALA) Releases Quarterly  Earnings Results, Misses Expectations By $0.06 EPSKala Pharmaceuticals (KALA) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS
www.americanbankingnews.com - March 27 at 7:25 AM
BRIEF-Kala Pharmaceuticals Posts Q4 Loss Per Share $0.46BRIEF-Kala Pharmaceuticals Posts Q4 Loss Per Share $0.46
www.reuters.com - March 26 at 11:10 AM
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial ResultsKala Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 26 at 11:10 AM
Kala Pharma reports 4Q lossKala Pharma reports 4Q loss
finance.yahoo.com - March 26 at 11:10 AM
Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference CallKala Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call
finance.yahoo.com - March 19 at 10:45 AM
Kala Pharmaceuticals Inc (KALA) Expected to Post Earnings of -$0.37 Per ShareKala Pharmaceuticals Inc (KALA) Expected to Post Earnings of -$0.37 Per Share
www.americanbankingnews.com - March 17 at 9:10 PM
Kala Pharmaceuticals Inc (KALA) Given Consensus Rating of "Buy" by AnalystsKala Pharmaceuticals Inc (KALA) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 16 at 1:54 AM
BRIEF-Kala Pharma Says Increased Size Of Board From 9 To 10BRIEF-Kala Pharma Says Increased Size Of Board From 9 To 10
www.reuters.com - March 5 at 10:59 AM
Emory University Acquires New Stake in Kala Pharmaceuticals Inc (KALA)Emory University Acquires New Stake in Kala Pharmaceuticals Inc (KALA)
www.americanbankingnews.com - March 4 at 2:59 PM
Kala Pharmaceuticals Inc (KALA) Given Consensus Rating of "Buy" by BrokeragesKala Pharmaceuticals Inc (KALA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 19 at 1:46 AM
Kala Pharmaceuticals (KALA) Stock Rating Upgraded by BidaskClubKala Pharmaceuticals (KALA) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - February 17 at 2:10 PM
Insider Buying: Kala Pharmaceuticals Inc (KALA) Major Shareholder Purchases 25,000 Shares of StockInsider Buying: Kala Pharmaceuticals Inc (KALA) Major Shareholder Purchases 25,000 Shares of Stock
www.americanbankingnews.com - February 12 at 6:30 PM
Zacks: Brokerages Expect Kala Pharmaceuticals Inc (KALA) Will Post Earnings of -$0.37 Per ShareZacks: Brokerages Expect Kala Pharmaceuticals Inc (KALA) Will Post Earnings of -$0.37 Per Share
www.americanbankingnews.com - February 12 at 3:16 AM
Kala Pharmaceuticals (KALA) Downgraded by BidaskClub to "Sell"Kala Pharmaceuticals (KALA) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - February 11 at 9:42 PM
Analyzing Kala Pharmaceuticals (KALA) and Summit Therapeutics (SMMT)Analyzing Kala Pharmaceuticals (KALA) and Summit Therapeutics (SMMT)
www.americanbankingnews.com - February 4 at 11:08 PM
Kala Pharmaceuticals Inc (KALA) Major Shareholder Acquires $5,433,600.00 in StockKala Pharmaceuticals Inc (KALA) Major Shareholder Acquires $5,433,600.00 in Stock
www.americanbankingnews.com - February 2 at 6:16 PM
Kala Pharmaceuticals Inc (KALA) Major Shareholder Purchases $339,806.80 in StockKala Pharmaceuticals Inc (KALA) Major Shareholder Purchases $339,806.80 in Stock
www.americanbankingnews.com - January 30 at 6:32 PM
Insider Buying: Kala Pharmaceuticals Inc (KALA) Major Shareholder Acquires 72,760 Shares of StockInsider Buying: Kala Pharmaceuticals Inc (KALA) Major Shareholder Acquires 72,760 Shares of Stock
www.americanbankingnews.com - January 30 at 6:14 PM
Kala Pharmaceuticals Inc (KALA) Sees Significant Growth in Short InterestKala Pharmaceuticals Inc (KALA) Sees Significant Growth in Short Interest
www.americanbankingnews.com - January 28 at 2:34 AM
Kala Pharmaceuticals Inc (KALA) Expected to Announce Earnings of -$0.37 Per ShareKala Pharmaceuticals Inc (KALA) Expected to Announce Earnings of -$0.37 Per Share
www.americanbankingnews.com - January 26 at 5:04 AM
Kala Pharmaceuticals (KALA) Earns Outperform Rating from Wells Fargo & CoKala Pharmaceuticals (KALA) Earns Outperform Rating from Wells Fargo & Co
www.americanbankingnews.com - January 26 at 12:22 AM
Kala Pharmaceuticals Inc (KALA) Receives Consensus Rating of "Buy" from AnalystsKala Pharmaceuticals Inc (KALA) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - January 25 at 1:40 AM
Kala Pharmaceuticals Inc (KALA) Major Shareholder Orbimed Advisors Llc Buys 64,637 SharesKala Pharmaceuticals Inc (KALA) Major Shareholder Orbimed Advisors Llc Buys 64,637 Shares
www.americanbankingnews.com - January 24 at 9:08 PM
Insider Buying: Kala Pharmaceuticals Inc (KALA) Major Shareholder Buys 74,931 Shares of StockInsider Buying: Kala Pharmaceuticals Inc (KALA) Major Shareholder Buys 74,931 Shares of Stock
www.americanbankingnews.com - January 24 at 9:08 PM
Kala Pharmaceuticals Inc (KALA) Major Shareholder Purchases $1,123,500.00 in StockKala Pharmaceuticals Inc (KALA) Major Shareholder Purchases $1,123,500.00 in Stock
www.americanbankingnews.com - January 24 at 9:08 PM
Kala Pharmaceuticals Inc (KALA) Short Interest Up 28.5% in DecemberKala Pharmaceuticals Inc (KALA) Short Interest Up 28.5% in December
www.americanbankingnews.com - January 14 at 2:32 AM
Kala Pharmaceuticals (KALA) Rating Increased to Hold at BidaskClubKala Pharmaceuticals (KALA) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - January 13 at 3:26 PM
Kala Pharmaceuticals Inc (KALA) Major Shareholder Orbimed Advisors Llc Purchases 240,484 SharesKala Pharmaceuticals Inc (KALA) Major Shareholder Orbimed Advisors Llc Purchases 240,484 Shares
www.americanbankingnews.com - January 12 at 6:26 PM
Kala Pharmaceuticals Inc (KALA) Major Shareholder Orbimed Advisors Llc Purchases 170,338 SharesKala Pharmaceuticals Inc (KALA) Major Shareholder Orbimed Advisors Llc Purchases 170,338 Shares
www.americanbankingnews.com - January 12 at 6:26 PM
BRIEF-Orbimed Advisors Reports About 11 Pct Passive Stake In Kala PharmaceuticalsBRIEF-Orbimed Advisors Reports About 11 Pct Passive Stake In Kala Pharmaceuticals
www.reuters.com - January 12 at 5:38 PM
Kala Pharmaceuticals Incs (KALA) Lock-Up Period To Expire  on January 16thKala Pharmaceuticals Inc's (KALA) Lock-Up Period To Expire on January 16th
www.americanbankingnews.com - January 9 at 1:22 AM
Kala Pharmaceuticals (KALA) Reports Mixed Results from Two Phase 3 Trials of KPI-121 0.25% in Dry Eye DiseaseKala Pharmaceuticals (KALA) Reports Mixed Results from Two Phase 3 Trials of KPI-121 0.25% in Dry Eye Disease
www.streetinsider.com - January 5 at 5:34 PM
Kala Pharma shares fall on mixed results from dry eye drug trialsKala Pharma shares fall on mixed results from dry eye drug trials
www.nasdaq.com - January 5 at 5:34 PM
UPDATE: Kala shares decline 8% on late-stage trial results for dry eye therapyUPDATE: Kala shares decline 8% on late-stage trial results for dry eye therapy
www.marketwatch.com - January 5 at 5:34 PM
Here's Why Kala Pharmaceuticals Got Crushed on FridayHere's Why Kala Pharmaceuticals Got Crushed on Friday
finance.yahoo.com - January 5 at 5:34 PM
Kala Pharmaceuticals (KALA) Buy Rating Reiterated at Wells Fargo & CoKala Pharmaceuticals' (KALA) Buy Rating Reiterated at Wells Fargo & Co
www.americanbankingnews.com - January 5 at 12:03 PM

SEC Filings

Kala Pharmaceuticals (NASDAQ:KALA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Kala Pharmaceuticals (NASDAQ:KALA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Kala Pharmaceuticals (NASDAQ KALA) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.